Monograph Details
|
|
Cardiovascular System
> Hypertension
|
|
KERLONE |
| Manufacturer |
|
Sanofi Aventis |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Cardioselective β-blocker. |
| Generic Name |
|
Betaxolol HCl 10mg+, 20mg; tabs; +scored. |
| Indications |
|
Hypertension. |
| Children |
|
Not recommended. |
| Adults |
|
Initially 10mg daily alone or added to diuretic therapy; may increase to 20mg daily after 7–14 days; usual max 20mg daily. Elderly or severe renal dysfunction: initially 5mg daily. |
| Contraindications |
|
Sinus bradycardia. 2nd- or 3rd-degree AV block. Cardiogenic shock. Overt heart failure. |
| Precautions |
|
CHF. Bronchospastic disease, COPD. Diabetes. Hyperthyroidism. Renal or hepatic dysfunction. Avoid abrupt cessation. Surgery. SLE. Elderly. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Increased cardiac effects of calcium channel blockers, digitalis. Bradycardia with catecholamine-depleting drugs. May block epinephrine. May interfere with glaucoma screening tests. |
| Adverse Reactions |
|
Bradycardia, headache, GI upset, dizziness, arthralgia, fatigue, dyspnea, chest pain, pharyngitis, impotence, heart failure, bronchospasm. |
| How Supplied |
|
Tabs—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
